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We examine the impact of pharmaceutical innovation on the longevity of Australians during the period
1995-2003. Due to the government's Pharmaceutical Benefits Scheme, Australia has much better data
on drug utilization than most other countries. We find that mean age at death increased more for diseases
with larger increases in mean drug vintage. The estimates indicate that increasing the mean vintage
of drugs by 5 years would increase mean age at death by almost 11 months. The estimates also indicate
that using newer drugs reduced the number of years of potential life lost before the ages of 65 and
70 (but not before age 75). During the period 1995-2003, mean age at death increased by about 2.0
years, from 74.4 to 76.4. The estimates imply that, in the absence of any increase in drug vintage, mean
age at death would have increased by only 0.7 years. The increase in drug vintage accounts for about
65% of the total increase in mean age at death. We obtain a rough estimate of the cost per life-year
gained from using newer drugs. Under our assumptions, using newer drugs (increasing drug vintage)
increased life expectancy by 1.23 years and increased lifetime drug expenditure by $12,976; the cost
per life-year gained from using newer drugs is $10,585. An estimate made by other investigators of
the value of a statistical Australian life-year ($70,618) is 6.7 times as large as our estimate of the cost
per life-year gained from using newer drugs.  We discuss several reasons why our estimate of the cost
per life-year gained from using newer drugs could be too high or too low.
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In previous papers, Lichtenberg (2005a, 2005b) has examined the impact of 
pharmaceutical innovation on longevity in the United States and in a group of developed 
and developing countries.  Due to data limitations, the measure of pharmaceutical 
innovation used in these studies was the cumulative number of drugs launched.  These 
studies provided support for the hypothesis that the introduction of new drugs has played 
an important role in increasing longevity. 
In this paper, we will examine the impact of pharmaceutical innovation on the 
longevity of Australians during the period 1995-2003.  In one important respect, the data 
available for Australia are much better than those used in the previous studies.  Rather 
than merely knowing whether a given drug has been launched in Australia by a certain 
date, we know how frequently that drug is used in each year.  Combining these data with 
data from other sources enables us to calculate the mean vintage
1 of drugs utilized in 
Australia, by disease and year.   
Section I contains a discussion of the “embodied technological progress 
hypothesis”.  Section II describes an econometric model to test this hypothesis.  Data 
sources and descriptive statistics are presented in Section III.  Empirical results are 
presented in Section IV.  Section V contains a summary and discussion. 
 
I.  Embodied technological progress hypothesis 
 
Economists believe that the development of new products is the main reason why 
people are better off today than they were several generations ago.  In their 1993 book, 
Innovation and Growth in the Global Economy, Grossman and Helpman argued that 
“innovative goods are better than older products simply because they provide more 
‘product services’ in relation to their cost of production.”  In their 1996 book, The 
Economics of New Goods, Bresnahan and Gordon stated simply that “new goods are at 
the heart of economic progress.” In a recent paper, Measuring the Growth from Better 
                                           
1 The dictionary contains several different definitions of vintage.  The definition we use is: “a period of 
origin or manufacture”.  We define the vintage of a drug as the year in which the U.S. Food and Drug 
Administration (FDA) first approved the drug’s active ingredient.  (The FDA, which has been in existence 
since 1938, provides the most complete data on drug vintage.)  For example, the vintage of Pharmaceutical 
Benefits Scheme items 8213G, 8214H, 8215J, and 8521L is 1997, the year the active ingredient of all these 
items (atorvastatin calcium) was approved by the FDA.   (These items correspond to 10, 20, 40, and 80 mg 
tablets, respectively.)   4
and Better Goods, Bils (2004) makes the case that “much of economic growth occurs 
through growth in quality as new models of consumer goods replace older, sometimes 
inferior, models.” 
We seek to test the hypothesis that, ceteris paribus, people using newer, or later 
vintage, drugs will be in better health, and will therefore live longer (die later).  This 
hypothesis is predicated on the idea that pharmaceuticals, like other R&D intensive 
products, are characterized by embodied technological progress. 
A number of econometric studies (Bahk and Gort (1993), Hulten (1992), 
Sakellaris and Wilson (2001, 2004)) have investigated the hypothesis that capital 
equipment employed by U.S. manufacturing firms embodies technological change, i.e. 
that each successive vintage of investment is more productive than the last. 
  Equipment is 
expected to embody significant technical progress due to the relatively high R&D-
intensity of equipment manufacturers.  The method that has been used to test the 
equipment-embodied technical change hypothesis is to estimate manufacturing 
production functions, including (mean) vintage of equipment as well as quantities of 
capital and labor.  These studies have concluded that technical progress embodied in 
equipment is a major source of manufacturing productivity growth.   
  Although most previous empirical studies of embodied technical progress have 
focused on equipment used in manufacturing, embodied technical progress may also be 
an important source of economic growth in health care.  One important input in the 
production of health—pharmaceuticals—is even more R&D-intensive than equipment.  
According to the National Science Foundation, the R&D intensity of drugs and medicines 
manufacturing is 74% higher than the R&D intensity of machinery and equipment 
manufacturing.  Therefore, it is quite plausible that there is also a high rate of 
pharmaceutical-embodied technical progress. 
  The hypothesis that technical progress is embodied in pharmaceuticals may be 
tested in two alternative ways.  One approach is to investigate whether the health and 
longevity of people with a given disease is positively related to the number of drugs that 
have been approved to treat that disease.
2  Lichtenberg adopted this approach in several 
                                           
2 In his model of endogenous technological change, Romer (1990) hypothesized the production function Y 
(AL)
1-α K
α, where Y = output, A = the “stock of ideas”, L = labor used to produce output, K = capital, and   5
studies (2005a, 2005b, 2005c); in all of them, he found that increases in the cumulative 
number of drugs improved health.  This approach allows one to distinguish between the 
effects of approval of “priority-review” drugs—drugs that the FDA considers to offer 
significant improvements over existing therapies—and approval of “standard-review” 
drugs—drugs that the FDA considers to be similar to previously approved drugs.  In two 
studies, Lichtenberg distinguished between the effects of priority-review and standard-
review drug approvals.  The results of distinguishing between the two were mixed.  
Lichtenberg (2005a) found that that approval of standard-review drugs had no effect on 
longevity, but that approval of priority-review drugs had a significant positive impact on 
longevity.   But most of the results in Lichtenberg (2005c) indicated that the difference 
between the effect of priority-and standard-review drugs on ability to work was not 
statistically significant. 
  The second way to test the hypothesis that technical progress is embodied in 
pharmaceuticals is to investigate whether the health and longevity of people with a given 
disease is positively related to the mean vintage (FDA approval year) of drugs used to 
treat the disease.  We believe that the second approach is superior to the first approach.  
The drugs that have been approved to treat a given disease influence the therapy that a 
patient could receive, but his health and longevity depend on the therapy he actually does 
receive.  The fact that a drug has been approved does not necessarily mean that it is 
commonly used.  In this paper we will pursue the second approach.   
Although we believe that mean vintage is a better measure of innovation than 
number of previously-approved drugs, proper accounting for the distinction between 
priority- and standard-review drugs when measuring drug vintage, while straightforward 
in theory, is difficult in practice.  Suppose a (standard-review) drug approved in 2008 is 
“therapeutically equivalent” to a drug approved in 1998.  Then the “effective vintage” of 
the drug is 1998, whereas its actual vintage is 2008.  (The effective vintage of a priority-
review drug is the same as its actual vintage.)  If we could measure the effective vintage 
of all drugs, we would use mean effective vintage instead of mean actual vintage in our 
econometric model.  However, although the FDA characterizes some drugs as 
                                                                                                                               
0 < α < 1.  The cumulative number of drugs approved is analogous to the stock of (FDA-approved) ideas.  
Health and longevity may be considered outputs of a health production function.   6
therapeutically equivalent to previously approved drugs, it does not specify the drugs to 
which they are therapeutically equivalent.  Hence measurement of mean effective vintage 
is not feasible. 
 
II.  Econometric model 
 
To test the hypothesis that pharmaceutical innovation has increased the longevity 
of Australians, we will estimate the following econometric model: 
 
Yit =  β [Σd N_RXdit FDA_YEARd / Σd N_RXdit] + αi + δt + εit    
 
or         Yit =                              β Vit                                 + αi + δt + εit     (1) 
 
where 
Yit   = a measure based on the age distribution of deaths from disease i 
in year t 
N_RXdit  = the number of times drug d was used to treat patients with 
disease i in year t 
FDA_YEARd  = the FDA approval year of the active ingredient of drug d 
Vit  = Σd Ndit FDA_YEARd / Σd Ndit  
= the mean vintage of drugs used to treat disease i in year t 
αi   = fixed disease effects 
δt   = fixed year effects 
   
There are both practical and theoretical reasons to define the vintage of a drug as 
the year the drug was approved by the U.S. FDA rather than the year the drug was listed 
(approved for reimbursement) in Australia’s Pharmaceutical Benefits Sceme (PBS).  Data 
on PBS listing dates are quite incomplete.  We obtained unpublished data on listing dates 
of drugs listed by the PBS after 1990.
3  Based on a sample of 311 drugs for which both 
FDA approval dates and PBS listing dates were available, we estimate that the mean lag 
between FDA approval and PBS listing is 3.6 years.  However we believe that the FDA 
approval date is theoretically superior to the PBS listing date as a measure of vintage 
(which is intended to indicate year of (global) market introduction or first use).  The 
vintage of a wine is the year the wine was bottled, not the year it was opened! 
                                           
3 We are grateful to Kim Sweeny of Victoria University for sharing these data with us.   7
In principle, health and longevity may be affected by lagged as well as current 
mean drug vintage.  However, including lagged vintage would substantially reduce the 
size of our sample since we have data on Y and V in only 9 years (1995-2003).  
Moreover, since vintage tends to be serially correlated, including lagged vintage terms 
would introduce multicollinearity.  We will therefore only include contemporaneous 
vintage in the model. 
We will estimate the model using 4 different dependent variables.  The first is the 
mean age at death of Australians dying from disease i in year t: 
AGE_DEATHit =  Σa (a N_DEATHait) / Σa N_DEATHait 
where N_DEATHait is the number of deaths at age a from disease i in year t.   
The second is the logarithm
4 of potential years of life lost before age 75 from 
disease i in year t: 
 LPYLL75it = ln[Σa max(75 – a, 0) N_DEATHait] 
The Australian Institute of Health and Welfare (AIHW) reports both mean age at death 
and potential years of life lost before age 75 in its General Records of Incidence of 
Mortality.  It also notes that the limit to life of 75 years is “arbitrary”.  We will also 
estimate models using two lower thresholds, 70 and 65:
5 
LPYLL70it = ln[Σa max(70 – a, 0) N_DEATHait] 
LPYLL65it = ln[Σa max(65 – a, 0) N_DEATHait] 
All models will be estimated via weighted least squares.  For the first model the 
weight is the number of deaths from disease i in year t: N_DEATH.it = Σa N_DEATHait. 
For the second model the weight is the mean number of potential years of life lost 
before age 75 from disease i during the 9 years 1995-2003: (1/9) Σt exp(LPYLL75it).  
Analogous weights will be used for the two lower age thresholds.   
Due to the presence of fixed disease effects and year effects, eq. (1) is a 
difference-in-differences model.  If the dependent variable is mean age at death, a 
positive and significant estimate of β would signify that there were above-average 
                                           
4 The logarithmic specification embodies the assumption that equal increases in vintage result in equal 
percentage reductions in potential years of life lost.   
5 The 70-year threshold is the one used in the OECD Health Database for making international 
comparisons.   The 65-year threshold is the “default choice” in the U.S. Center for Disease Control’s Years 
of Potential Life Lost Reports <http://www.cdc.gov/ncipc/wisqars/fatal/help/definitions.htm>.   8
increases in mean age at death for diseases with above-average increases in mean vintage 
of drugs. 
 
III.  Data sources and descriptive statistics 
 
Mortality data.  The AIHW has compiled long-term mortality data on selected causes of 
death by age and sex for each year from the beginning of the 20th century, and published 
them in its GRIM (General Record of Incidence of Mortality) books. These are 
interactive Excel workbooks updated annually containing comprehensive long-term 
mortality data on selected causes of death by age and sex for each year. The GRIM books 
have been grouped together by chapters as adopted by the 10th Revision of the 
International Statistical Classification of Diseases and Related Health Problems (ICD-
10). Each workbook contains mortality data, population data, derived data items (e.g. 
age-specific and age-standardised rates), summary measures (e.g. mean age at death, 
potential years of life lost, lifetime risk of dying), birth cohort information and graphs. 
  The following table shows annual mortality data for all causes of death combined 







Years of life lost 
before age 75 
Years of life lost before age 
75 per 1,000 population 
1995 125,133  71.8  966,458  56.2 
1996 128,719  72.2  963,160  55.3 
1997 129,350  72.4  959,548  54.6 
1998 127,202  72.4  941,793  53.1 
1999 128,102  72.6  938,078  52.4 
2000 128,291  73.0  908,058  50.2 
2001 128,544  73.3  881,733  48.2 
2002 133,707  73.8  876,770  47.4 
2003 132,292  73.9  866,298  46.4 
 
Pharmaceutical utilization data.  Data on pharmaceutical utilization were obtained from 
the National Social Health Statistical Data Library (HealthWIZ)
6 a database on CD-ROM 
that is used to disseminate comprehensive population health related statistical datasets, 
across the Australian health services sector, for the purposes of clinical research, policy 
                                           
6 http://www.health.gov.au/internet/wcms/publishing.nsf/Content/Healthwiz-1   9
development and health services planning, particularly in regional areas.  Several datasets 
contained in HealthWIZ are derived from the Australian Government’s Pharmaceutical 
Benefits Scheme (PBS).
7 
For nearly 60 years, the PBS has provided reliable, timely and affordable access 
to a wide range of medicines for all Australians.  Many medicines cost the Government 
much more than the price paid by the patient – some cost hundreds, even thousands of 
dollars, but the government provides a subsidy so that patients pay much less. The patient 
receives the benefit of this subsidy when she has her prescription for a medicine filled 
under the PBS.  Current provisions governing the operations of the PBS are embodied in 
Part VII of the National Health Act 1953 together with the National Health 
(Pharmaceutical Benefits) Regulations 1960 made under the Act.  The scheme has proven 
itself to be one of the best drug subsidy systems in the world and around 80% of 
prescriptions dispensed in Australia are subsidized under the PBS.
8  Every time a patient 
fills a prescription for a PBS medicine, she receives a subsidy.  From 1 January 2006, the 
patient pays up to $29.50 for most PBS medicines or $4.70 if she has a concession card. 
The Australian Government pays the remaining cost.  The PBS covered around 170 
million prescriptions in the year to June 2005. This equates to about eight prescriptions 
per person in Australia for the year.  With new and more effective medicines helping us 
to lead longer and healthier lives, the PBS is growing each year. The cost of the PBS is 
currently around $6.0 billion per year.  
  HealthWIZ provides data on the number of prescriptions filled under the PBS, by 
drug and year, 1995-2004.  This dataset contained information about approximately 700 
drugs.  The Anatomical Therapeutic Chemical (ATC) Classification System is used for 
the classification of drugs. It is controlled by the WHO Collaborating Centre for Drug 
Statistics Methodology, and was first published in 1976.  Drugs are divided into different 
groups according to the organ or system on which they act and/or their therapeutic and 
                                           
7 http://www.health.gov.au/internet/wcms/publishing.nsf/Content/health-pbs-general-aboutus.htm 
8 Some of the reasons why a medicine may not be available on the PBS are: (1) the manufacturer has not 
registered its product to treat a particular condition with the Therapeutic Goods Administration; (2) the 
manufacturer did not apply to the government’s independent expert committee – the Pharmaceutical 
Benefits Advisory Committee (PBAC) – to list the medicine on the PBS; and (3) the manufacturer hasn’t 
supplied sufficient evidence, or the evidence supplied does not support a recommendation by the PBAC.  
http://www.health.gov.au/internet/main/publishing.nsf/Content/health-pbs-general-faq.htm-copy2    10
chemical characteristics.  In the system drugs are classified into groups at 5 different 
levels.  There are 14 main groups at the first level.   
  To illustrate the pharmaceutical utilization data, the following is a list of the top 
10 cardiovascular system drugs, ranked by number of prescriptions in 2004: 
 










perindopril and diuretics  1,522,659 
 
The following is a list of the top 10 antineoplastic and immunomodulating agents, ranked 
by number of prescriptions in 2004: 
 









interferon beta-1b  32,282 
fluorouracil 29,160 
 
Pharmaceutical vintage data.  We used data from the Drugs@FDA database
9 and 
Mosby’s Drug Consult
10 to determine the year in which each active ingredient was first 
approved by the FDA. 
Descriptive statistics on the mean vintage of PBS prescriptions.   As the following table 
shows, during the period 1995-2004 the mean vintage of PBS prescriptions increased by 
                                           
9 http://www.fda.gov/cder/drugsatfda/datafiles/default.htm 
10 http://www.mosbysdrugconsult.com/   11
about 1 year per year, from 1977.8 to 1986.7.  The average PBS prescription is for a 17 
year-old drug. 
year  Number of rx’s  Mean FDA approval year 
1995 122,224,901  1977.8 
1996 125,904,079  1978.8 
1997 124,980,656  1979.8 
1998 125,365,284  1980.9 
1999 133,455,864  1981.9 
2000 142,877,869  1983.1 
2001 150,924,801  1984.4 
2002 158,172,125  1985.3 
2003 161,192,358  1986.1 
2004 170,253,375  1986.7 
 
  The level and growth rate of vintage varies considerably across ATC groups.  
Figure 1 depicts the mean vintage of two classes of drugs during 1995-2003.  
Cardiovascular drugs tend to be much newer than antineoplastic and immunomodulating 
agents; in 2003 the vintage of the latter was almost 10 years lower.  The mean vintage of 
cardiovascular system drugs increased almost twice as much during the first half of this 
period (1995-1999) as it did during the second half (1999-2003).    In contrast, the mean 
vintage of antineoplastic and immunomodulating agents increased over four times as 
much in the second half as it did in the first half.   
Linkage of drugs to diseases.  Estimation of eq. (1) requires linkage of drugs to the 
diseases they are used to treat.  We used the following linkage of ATC drug groups to 
ICD-10 causes of death chapters:
11 
ATC Drug Group(s)  ICD-10 Cause of Death Chapter(s) 
Alimentary tract and metabolism (A) + 
systemic hormonal preparations, 
excluding sex hormones and insulins (H) 
Diseases of the digestive system (XI) + 
endocrine, nutritional and metabolic 
diseases (IV) 
Blood and blood forming organs (B) 
Diseases of the blood and blood-forming 
organs (III) 
Cardiovascular system (C)  Diseases of the circulatory system (IX) 
                                           
11 The following ICD-10 chapters are excluded from our analysis: pregnancy, childbirth and the puerperium 
(XV); certain conditions originating in the perinatal period (XVI); congenital malformations, deformations 
and chromosomal abnormalities (XVII); symptoms, signs and abnormal clinical and laboratory findings  
(XVIII);injury, poisoning and certain other consequences of external causes (XIX); external causes of 
morbidity and mortality (XX); factors influencing health status and contact with health services (XXI); 
codes for special purposes (XXII).   12
Dermatologicals (D) 
Diseases of the skin and subcutaneous 
tissue (XII) 
Genito-urinary system and sex hormones 
(G) 
Diseases of the genitourinary system 
(XIV) 
Anti-infectives for systemic use (J) + 
antiparasitic products, insecticides and 
repellents (P) 
Certain infectious and parasitic 
diseases (I) 
Antineoplastic and immunomodulating 
agents (L)  Neoplasms (II) 
Musculo-skeletal system (M) 
Diseases of the musculoskeletal system 
and connective tissue (XIII) 
Nervous system (N) 
Diseases of the nervous system (VI) + 
mental and behavioural disorders (V) 
Respiratory system (R)  Diseases of the respiratory system (X) 
Sensory organs (S) 
Diseases of the eye and adnexa (VII) + 
diseases of the ear and mastoid process 
(VIII) 
 
IV.  Empirical results 
 
  Estimates of eq. (1) with four different dependent variables are shown in Table 
1.
12  The equations were estimated using annual data for the period 1995-2003 on the 
eleven groups of diseases shown above: N = 99 (11 diseases * 9 years).  All equations 
include disease fixed effects and year fixed effects.   
  The dependent variable of the first equation is the mean age at death of 
Australians dying from disease i in year t.  As shown in line 1, the coefficient on the 
mean vintage of drugs is positive and statistically significant (p-value = 0.0497).  This 
indicates that mean age at death increased more for diseases with larger increases in mean 
drug vintage.  The point estimate of β indicates that increasing the mean vintage of drugs 
by 5 years would increase mean age at death by almost 11 months.  Additional 
implications of the estimates of the first model will be considered below.  Before doing 
that, we will discuss estimates of the other three models.   
  As shown in line 11, when the dependent variable is the logarithm of potential 
years of life lost before age 75 from disease i in year t, the coefficient on the mean 
vintage of drugs is negative but not statistically significant (p-value = 0.1787).  However, 
as shown in lines 21 and 31, when the age threshold is either 70 or 65, the coefficient on 
                                           
12 Data used to estimate eq. (1) are shown in Appendix Table 1.   13
the mean vintage of drugs is negative and statistically significant (p-value = 0.0488 and 
0.0135, respectively).  This implies that using newer drugs has reduced premature 
mortality—especially mortality before age 65—in the Australian population.
13  The 
estimates of the three potential years of life lost equations tend to confirm the estimates 
of the mean age at death equation. 
  We can use our estimates of the first equation to compare the actual increase in 
mean age at death during the period 1995-2003 to the increase that would have occurred 
in the absence of any increase in drug vintage.
14  As shown in Figure 2, during this 
period, mean age at death increased by about 2.0 years, from 74.4 to 76.4.  The estimates 
imply that, in the absence of any increase in drug vintage, mean age at death would have 
increased by only 0.7 years.  The increase in drug vintage accounts for about 65% of the 
total increase in mean age at death.   
  We can also obtain a rough estimate of the cost per life-year gained from using 
newer drugs.  The calculations are shown in the following table.   
     year   
     1995  2003  change 
1 rx  expenditure
15 $2,672,000,000 $6,268,000,000     
2 population  18,071,758 19,872,646    
3  rx expenditure per capita ((2)/(1))  $148 $315    
4  life expectancy (mean age at 
death) 75.13 76.36  1.23
5  “lifetime” rx expenditure per 
capita ((4) * (3))  $11,109 $24,085  $12,976
 
Line 3 shows that per capita drug expenditure more than doubled in Australia from 1995 
to 2003, from $148 to $315.  For simplicity, suppose that all of this increase was due to 
the fact that the drugs used in 2003 were newer than those used in 1995.  Line 4 shows 
the increase in “life expectancy” (mean age at death) that is attributable to increasing 
drug vintage.  Line 5 shows “lifetime” drug expenditure per capita: annual expenditure 
                                           
13 The magnitude of the point estimate in line 31 is about 35% larger than the magnitude of the point 
estimate in line 21.  But since the number of years of potential life lost before age 70 is about 47% higher 
than the number of years of potential life lost before age 65, these two models yield similar estimates of the 
absolute reduction in years of potential life lost from increasing drug vintage. 
14 The increase that would have occurred in the absence of any increase in drug vintage is measured by the 
differences between the year fixed effects shown in lines 2-10 of Table 1. 
15 Source: OECD Health Database.   14
times life expectancy.  Under our assumptions, using newer drugs (increasing drug 
vintage) increased life expectancy by 1.23 years and increased lifetime drug expenditure 
by $12,976.  The cost per life-year gained from using newer drugs is $10,585 (= 
$12,976/1.23).    
  Viscusi (2005), citing Kniesner and Leeth (1991), estimates that the value of a 
statistical Australian life is 4.2 million USD, which is equal to $A 5.4 million at the 
current exchange rate (1.2839 $A/USD).  This implies that the value of a statistical 
Australian life-year is $70,618 (=$A 5.4 million / 76.4).  This value is 6.7 times as large 
as our estimate of the cost per life-year gained from using newer drugs. 
 
V.  Summary and discussion 
 
We have examined the impact of pharmaceutical innovation on the longevity of 
Australians during the period 1995-2003.  Due to the government’s Pharmaceutical 
Benefits Scheme, Australia has much better data on drug utilization than most other 
countries.   
We found that mean age at death increased more for diseases with larger increases 
in mean drug vintage.  The estimates indicated that increasing the mean vintage of drugs 
by 5 years would increase mean age at death by almost 11 months.  The estimates also 
indicated that using newer drugs reduced the number of years of potential life lost before 
the ages of 65 and 70 (but not before age 75).   
During the period 1995-2003, mean age at death increased by about 2.0 years, 
from 74.4 to 76.4.
16  The estimates implied that, in the absence of any increase in drug 
vintage, mean age at death would have increased by only 0.7 years.  The increase in drug 
vintage accounts for about 65% of the total increase in mean age at death.   
  We obtained a rough estimate of the cost per life-year gained from using newer 
drugs.  Under our assumptions, using newer drugs (increasing drug vintage) increased life 
expectancy by 1.23 years and increased lifetime drug expenditure by $12,976; the cost 
                                           
16 Lichtenberg (2005a) found that, in the U.S., within-disease increases in mean age at death accounted for 
about 80% of the aggregate long-term increase in mean age at death; the remaining 20% was due to a shift 
in the distribution of fatal diseases.   15
per life-year gained from using newer drugs is $10,585.
17   An estimate made by other 
investigators of the value of a statistical Australian life-year ($70,618) is 6.7 times as 
large as our estimate of the cost per life-year gained from using newer drugs. 
For several reasons, our estimate of the cost per life-year gained from using newer 
drugs could be too high or too low.  Studies based on U.S. data (Lichtenberg (2001, 
2005c, 2006)) indicate that use of newer drugs reduces admissions to hospitals and 
nursing homes, and increases ability to work.  By not accounting for this, we may have 
overestimated the cost per Australian life-year gained. 
Use of newer drugs may have cross-disease spillover effects: using newer drugs 
for one disease may either increase or decrease mortality from other diseases (in part due 
to “competing risks”).  Such spillovers could be either negative or positive.  For example, 
using a newer drug to treat cancer might reduce cancer mortality but increase life-years 
lost due to cardiovascular disease.  On the other hand, using a newer drug to treat 
depression and other mental disorders might lead to better management of cardiovascular 
disease. 
Finally, innovation in medical devices and procedures, as well as in drugs, have 
undoubtedly contributed to Australian longevity increase.
18  The models we have 
estimated control (via year fixed effects) for device/procedure innovation that is common 
to all diseases, but not for disease-specific device/procedure innovation: measuring 
disease-specific device/procedure innovation is far more challenging than measuring 
disease-specific drug innovation.  Since device/procedure innovation may either 
substitute for or complement drug innovation, controlling for disease-specific 
device/procedure innovation could either decrease or increase our estimate of the cost per 
life-year gained from using newer drugs.   
Our findings, which are based on aggregate data, are broadly consistent with 
previous findings based on individual-level data.  Lichtenberg and Virabhak (2007) 
examined the impact of drug vintage on health and longevity using data on (American) 
individuals before and after the drugs were consumed.  They found that people who used 
                                           
17 This is an estimate of the cost per life-year gained from using newer drugs in general.  It is likely that the 
cost per life-year gained from some newer drugs is higher, and from other newer drugs is lower, than this 
average. 
18 However, the biopharmaceutical industry is much more R&D-intensive than the medical device and 
equipment industry.   16
newer drugs had better post-treatment health than people using older drugs for the same 
condition, controlling for pre-treatment health, age, sex, race, marital status, education, 
income, and insurance coverage: they were more likely to survive, their perceived health 
status was higher, and they experienced fewer activity, social, and physical limitations.  
Most of the health measures indicated that the effect of drug vintage on health is higher 
for people with low initial health than it is for people with high initial health.  This 
suggests that pharmaceutical-embodied technical progress has a tendency to reduce 
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eLine Parameter Estimate StdErr tValue Probt
1 fda_year 0.182 0.091 1.99 0.0497
2 year 1995 -0.752 0.688 -1.09 0.2777
3 year 1996 -0.506 0.627 -0.81 0.4219
4 year 1997 -0.559 0.569 -0.98 0.3291
5 year 1998 -0.576 0.498 -1.16 0.2514
6 year 1999 -0.275 0.456 -0.60 0.5487
7 year 2000 -0.231 0.374 -0.62 0.5386
8 year 2001 -0.153 0.329 -0.46 0.6440
9 year 2002 0.034 0.304 0.11 0.9112
10 year 2003 0.000 . . .
11 fda_year -0.015 0.011 -1.36 0.1787
12 year 1995 -0.008 0.089 -0.09 0.9262
13 year 1996 -0.001 0.084 -0.01 0.9910
14 year 1997 0.013 0.077 0.16 0.8708
15 year 1998 0.000 0.069 0.00 0.9984
16 year 1999 -0.032 0.065 -0.49 0.6274
17 year 2000 -0.023 0.053 -0.44 0.6640
18 year 2001 -0.025 0.046 -0.54 0.5940
19 year 2002 -0.008 0.043 -0.19 0.8463
20 year 2003 0.000 . . .
21 fda_year -0.024 0.012 -2.00 0.0488
22 year 1995 -0.087 0.098 -0.89 0.3763
23 year 1996 -0.072 0.092 -0.78 0.4349
24 year 1997 -0.047 0.084 -0.55 0.5819
25 year 1998 -0.044 0.076 -0.58 0.5609
26 year 1999 -0.075 0.072 -1.05 0.2958
27 year 2000 -0.050 0.059 -0.85 0.3982
28 year 2001 -0.046 0.052 -0.88 0.3816
29 year 2002 -0.021 0.049 -0.43 0.6714
30 year 2003 0.000 . . .
31 fda_year -0.033 0.013 -2.53 0.0135
32 year 1995 -0.147 0.107 -1.37 0.1741
33 year 1996 -0.125 0.101 -1.24 0.2175
34 year 1997 -0.087 0.093 -0.94 0.3483
35 year 1998 -0.069 0.083 -0.83 0.4094
36 year 1999 -0.100 0.079 -1.28 0.2058
37 year 2000 -0.063 0.066 -0.97 0.3355
38 year 2001 -0.059 0.058 -1.01 0.3139
39 year 2002 -0.029 0.055 -0.53 0.5961
40 year 2003 0.000 . . .
dep. var. = LPYLL65it; weight = (1/9) Σt exp(LPYLL65it)
Table 1
Estimates of eq. (1)
dep. var. = AGE_DEATHit; weight = N_DEATHit
dep. var. = LPYLL75it; weight = (1/9) Σt exp(LPYLL75it)
dep. var. = LPYLL70it; weight = (1/9) Σt exp(LPYLL70it)Figure 2
Comparison of actual increase in mean age at death to the 





























if no increase in drug vintage
actualDisease







Mean age at 
death
Potential 
years of life 
lost before 
age 65
Digestive & Endocrine 1995 16,316,361 1982.8 7,448 73.0 23,090
Digestive & Endocrine 1996 17,133,504 1983.4 7,783 73.1 24,213
Digestive & Endocrine 1997 17,533,563 1984.0 8,154 72.7 28,023
Digestive & Endocrine 1998 17,918,165 1984.7 7,932 72.8 27,585
Digestive & Endocrine 1999 19,188,559 1985.1 8,321 73.4 26,993
Digestive & Endocrine 2000 20,147,558 1985.5 8,301 74.0 23,785
Digestive & Endocrine 2001 20,385,191 1986.1 8,403 74.2 24,213
Digestive & Endocrine 2002 22,400,650 1987.4 9,125 74.2 27,298
Digestive & Endocrine 2003 23,330,710 1988.7 9,222 74.4 26,658
Blood 1995 1,782,830 1953.2 871 54.8 13,788
Blood 1996 1,889,272 1953.3 433 72.4 1,995
Blood 1997 1,950,002 1953.7 372 73.9 1,658
Blood 1998 2,167,689 1954.2 436 72.5 2,358
Blood 1999 2,636,979 1954.8 450 71.1 2,655
Blood 2000 3,366,276 1958.9 413 72.5 2,143
Blood 2001 3,726,524 1964.2 408 72.3 1,818
Blood 2002 4,407,413 1967.9 428 74.1 1,870
Blood 2003 5,053,317 1970.2 454 74.5 1,670
Circulatory 1995 29,274,934 1983.0 53,407 77.6 65,548
Circulatory 1996 31,445,238 1984.1 53,990 77.9 64,778
Circulatory 1997 33,112,134 1984.9 53,636 78.1 65,435
Circulatory 1998 34,601,496 1985.9 51,787 78.2 62,868
Circulatory 1999 38,246,147 1986.9 51,303 78.5 61,273
Circulatory 2000 42,380,643 1987.7 49,687 78.7 59,848
Circulatory 2001 45,401,307 1988.2 49,326 78.8 61,038
Circulatory 2002 48,340,917 1988.6 50,294 79.1 58,803
Circulatory 2003 50,585,429 1989.0 48,835 79.1 61,090
Skin 1995 4,158,948 1964.6 250 80.5 260
Skin 1996 3,935,264 1966.3 175 80.9 130
Skin 1997 3,189,000 1964.9 240 78.9 515
Skin 1998 2,748,965 1964.8 260 80.5 178
Skin 1999 2,919,539 1966.3 289 79.1 433
Skin 2000 3,003,996 1967.2 252 80.0 253
Skin 2001 2,969,818 1968.0 265 80.6 203
Skin 2002 2,870,937 1968.1 334 80.0 455
Skin 2003 2,757,778 1968.4 305 80.7 183
Genitourinary 1995 6,272,147 1976.6 2,074 79.2 1,878
Genitourinary 1996 6,239,411 1976.6 2,244 79.6 1,890
Genitourinary 1997 5,471,427 1978.3 2,588 80.1 2,095
Genitourinary 1998 5,323,027 1979.3 2,697 80.3 2,230
Genitourinary 1999 5,701,087 1979.5 2,768 80.7 2,195
Genitourinary 2000 5,878,884 1980.0 2,692 80.6 2,043
Genitourinary 2001 6,013,677 1980.8 2,812 81.0 1,868
Genitourinary 2002 5,423,044 1981.2 2,983 81.1 1,850
Appendix Table 1
Data used to estimate eq. (1)Disease







Mean age at 
death
Potential 
years of life 
lost before 
age 65
Genitourinary 2003 4,244,974 1981.4 3,001 80.8 2,350
Infectious 1995 17,079,435 1972.3 1,070 68.7 7,463
Infectious 1996 16,263,453 1972.7 1,638 62.1 18,278
Infectious 1997 15,199,509 1973.1 1,522 67.1 12,308
Infectious 1998 14,470,051 1973.5 1,454 68.7 10,513
Infectious 1999 13,523,718 1974.5 1,603 69.9 10,458
Infectious 2000 13,504,891 1974.7 1,646 70.4 10,290
Infectious 2001 13,487,633 1974.6 1,675 70.6 10,413
Infectious 2002 13,096,864 1974.8 1,790 71.0 10,578
Infectious 2003 12,745,328 1975.1 1,754 72.0 8,958
Neoplasms 1995 487,908 1972.6 34,368 70.1 115,888
Neoplasms 1996 534,042 1972.7 35,252 70.3 118,093
Neoplasms 1997 570,489 1973.2 35,363 70.3 117,395
Neoplasms 1998 605,012 1973.8 35,609 70.5 117,388
Neoplasms 1999 697,621 1973.7 35,856 70.9 114,630
Neoplasms 2000 829,760 1976.1 36,374 71.2 111,575
Neoplasms 2001 923,797 1977.7 37,497 71.3 115,190
Neoplasms 2002 1,008,548 1978.7 38,426 71.5 115,128
Neoplasms 2003 1,049,238 1979.3 38,392 71.5 115,990
Musculoskeletal 1995 5,956,861 1978.6 734 75.5 1,698
Musculoskeletal 1996 5,833,568 1978.7 794 76.6 1,438
Musculoskeletal 1997 5,636,378 1978.9 792 75.6 1,815
Musculoskeletal 1998 5,430,948 1978.9 751 75.1 1,805
Musculoskeletal 1999 5,669,394 1979.0 862 76.3 1,735
Musculoskeletal 2000 6,784,075 1983.7 852 76.2 1,900
Musculoskeletal 2001 9,639,186 1990.2 896 77.4 1,315
Musculoskeletal 2002 11,380,343 1991.5 1,015 77.5 1,715
Musculoskeletal 2003 12,012,146 1992.0 999 77.6 1,790
Mental & Nervous 1995 22,947,117 1973.6 6,142 72.5 36,365
Mental & Nervous 1996 23,993,807 1974.7 6,631 73.6 35,608
Mental & Nervous 1997 24,577,524 1976.6 6,591 71.9 40,780
Mental & Nervous 1998 25,121,805 1978.1 6,589 71.8 41,660
Mental & Nervous 1999 26,843,646 1979.5 6,698 73.6 33,388
Mental & Nervous 2000 28,269,319 1980.9 7,113 73.2 38,765
Mental & Nervous 2001 30,211,670 1982.6 6,908 75.9 25,475
Mental & Nervous 2002 31,017,021 1983.9 7,794 76.8 24,618
Mental & Nervous 2003 31,579,863 1984.8 7,565 76.9 24,383
Respiratory 1995 11,063,249 1981.1 9,431 75.6 17,180
Respiratory 1996 11,875,706 1982.0 10,294 76.5 15,228
Respiratory 1997 11,297,442 1982.5 10,349 76.8 15,028
Respiratory 1998 10,649,965 1984.3 9,614 76.8 14,543
Respiratory 1999 11,232,232 1985.2 9,613 77.2 13,365
Respiratory 2000 11,419,935 1986.1 10,907 77.9 13,695
Respiratory 2001 10,362,935 1986.0 10,626 77.7 14,515
Respiratory 2002 10,165,471 1986.9 11,668 78.3 13,790
Respiratory 2003 9,751,515 1988.8 11,892 78.7 14,380
Eye & Ear 1995 5,857,233 1969.4 16 47.5 440Disease







Mean age at 
death
Potential 
years of life 
lost before 
age 65
Eye & Ear 1996 5,734,316 1968.4 18 53.1 390
Eye & Ear 1997 5,499,593 1968.6 9 69.7 75
Eye & Ear 1998 5,478,050 1970.0 15 71.8 93
Eye & Ear 1999 5,927,943 1973.2 11 64.3 143
Eye & Ear 2000 6,298,017 1975.9 10 59.5 143
Eye & Ear 2001 6,671,412 1977.5 10 74.5 40
Eye & Ear 2002 6,847,396 1978.7 8 63.1 113
Eye & Ear 2003 6,820,565 1979.4 15 64.5 213